Sirtuin 1 Activity in Peripheral Blood Mononuclear Cells of Patients with Osteoporosis

Background Sirtuin 1 (SIRT1) is a class III histone deacetylase that may play a critical role in several biological functions, including lifespan, stress, and inflammation. Our main objective was to evaluate SIRT1 activity in peripheral blood mononuclear cells (PBMCs) in patients with osteoporosis and to analyze the relationship between the SIRT 1 activity and markers of inflammation and bone remodelling. Material/Methods We performed a prospective monocentric study of patients with osteoporosis and measured the nuclear and cytoplasmic activities of SIRT1 in PBMCs. Levels of proinflammatory cytokines were assessed in culture supernatants of PBMCs isolated from the osteoporosis patients. The level of serum C-terminal cross-linking telopeptide of type I collagen (CTX), a marker of bone resorption, was measured in the serum of osteoporosis patients. Results Sixteen women with osteoporosis were included. A statistically significant correlation between the cytoplasmic and nuclear SIRT 1 activities was found in PBMCs of patients with osteoporosis. Although non-significant, we observed a negative trend between nuclear SIRT 1 activity and the rate of serum CTX and a positive trend between IL-6 and CTX levels in patients with osteoporosis. Conclusions This study shows that the cytoplasmic and nuclear SIRT 1 activities are measurable in circulating PBMCs of patients with osteoporosis and that these 2 activities are correlated. The potential role of inflammation in bone resorption in patients with osteoporosis was also studied.

[1]  W. Abbas,et al.  Imbalance between HAT and HDAC Activities in the PBMCs of Patients with Ankylosing Spondylitis or Rheumatoid Arthritis and Influence of HDAC Inhibitors on TNF Alpha Production , 2013, PloS one.

[2]  W. Abbas,et al.  Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis , 2013, Clinical Epigenetics.

[3]  E. Lespessailles,et al.  2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. , 2012, Joint, bone, spine : revue du rhumatisme.

[4]  G. Schett,et al.  Pathways for Bone Loss in Inflammatory Disease , 2012, Current Osteoporosis Reports.

[5]  C. Cooper,et al.  Epigenetic influences in the developmental origins of osteoporosis , 2012, Osteoporosis International.

[6]  M. Yen,et al.  Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  D. Toiber,et al.  Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. , 2011, Endocrinology.

[8]  A. Mobasheri,et al.  Resveratrol-mediated SIRT-1 Interactions with p300 Modulate Receptor Activator of NF-κB Ligand (RANKL) Activation of NF-κB Signaling and Inhibit Osteoclastogenesis in Bone-derived Cells , 2011, The Journal of Biological Chemistry.

[9]  G. Andersson,et al.  Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. , 2010, Biochemical and biophysical research communications.

[10]  G. Herbein,et al.  Histone deacetylases in viral infections , 2010, Clinical Epigenetics.

[11]  P. Tak,et al.  Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? , 2008, Arthritis research & therapy.

[12]  K. Shimamoto,et al.  Nucleocytoplasmic Shuttling of the NAD+-dependent Histone Deacetylase SIRT1* , 2007, Journal of Biological Chemistry.

[13]  C. Bäckesjö,et al.  Activation of Sirt1 Decreases Adipocyte Formation During Osteoblast Differentiation of Mesenchymal Stem Cells , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  S. Renaud,et al.  Wine, alcohol, platelets, and the French paradox for coronary heart disease , 1992, The Lancet.